US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive… EP News Bureau Dec 15, 2020 Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional…
